Pacific Research Institute
Recent News About Pacific Research Institute
-
Gov’t Spending Watchdog: Federal drug program serving CA hospitals benefits ‘special interests’ over patients
Citizens Against Government Waste (CAGW) said that hospitals and other “special interests,” rather than patients, are benefiting from a federal drug discount program in which up to 174 California hospitals participate.
-
Pacific Research Institute senior fellow: 'Spending billions' on housing under Project Homekey isn't easing homeless problem
California is leading the nation in one not-so-noteworthy category: Homelessness continues to surge while it's starting to ease in other states.
-
CA Health Analyst: Congress should fix the 340b drug discount program 'mess'
Spending on prescription drugs purchased at participating health care providers through the federal 340b drug discount program increased 19% annually between 2010 and 2021.
-
Rx drug spending up 19% through federal program that includes 172 California hospitals
Spending on prescription drugs purchased at participating health care providers through the federal 340b drug discount program increased 19% annually between 2010 and 2021.
-
CA Health Analyst: Inflation Reduction Act ‘bankrolls billions of dollars' worth of left-wing policy priorities at the expense of life-saving pharmaceutical innovation’
The head of the Pasadena-based Pacific Research Institute (PRI) said that a drug provision in the “Inflation Reduction Act” could lead to a decrease in health care innovation.
-
162 California biopharma companies could be negatively impacted by Inflation Reduction Act drug provision
A provision of the “Inflation Reduction Act” (IRA) could threaten investments in and by 162 California biopharma companies involved in what’s called “Small Molecule” drug development.
-
Finance research analyst: The shift to ESG and market influence is ‘all about control’
Paul Tice, a writer, analyst, and adjunct professor, suggests that the rise of ESG investing reflects a shift towards exerting control over capital flows and implementing government-directed agendas, diverging from traditional profit-maximizing approaches in finance. Tice was a guest on a recent episode of the Next Round Podcast.
-
Finance research analyst: ‘ESG is just the latest, shiniest object’ amidst evolving market trends and regulatory concerns
Paul Tice, a writer, analyst, and adjunct professor, suggests that the prolonged stability in the market until 2020 led to a continuous search for new trends, with ESG becoming the latest focus amid Wall Street's shift towards a less innovative and more compliant approach. Tice was a guest on a recent episode of Next Round Podcast.
-
Finance research analyst: The UN has ‘no place giving investment advice’
Paul Tice, writer, analyst, and adjunct professor, asserts that the UN's aspiration to offer investment advice exposes a significant strategic drift due to its lack of financial expertise, highlighting a broader trend of pursuing control over the financial market. Tice was a guest on a recent episode of Next Round Podcast.
-
Health Policy Analyst: Biden’s proposed expanded drug negotiations would lessen ‘our ability to fund R and D for future cures’
Sally Pipes, president of the Pacific Research Institute (PRI), said that the expanded Medicare drug price negotiations proposed by President Biden in his State of the Union address would be “detrimental” to research and development for “future cures.”